Your browser doesn't support javascript.
loading
Personalizing non-small cell lung cancer treatment through patient-derived xenograft models: preclinical and clinical factors for consideration.
Fuchs, Vered; Sobarzo, Ariel; Msamra, Maha; Kezerle, Yarden; Linde, Liat; Sevillya, Gur; Anoze, Alaa; Refaely, Yael; Cohen, Ahron Yehonatan; Melamed, Israel; Azriel, Amit; Shoukrun, Rami; Raviv, Yael; Porgador, Angel; Peled, Nir; Roisman, Laila Catalina.
Afiliación
  • Fuchs V; The Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.
  • Sobarzo A; The Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.
  • Msamra M; The Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.
  • Kezerle Y; Institute of Pathology, Soroka University Medical Center, Beer-Sheva, Israel.
  • Linde L; Biomedical Core Facility, Russell Berrie Nanotechnology Institute, Technion-Israel Institute of Technology, Haifa, Israel.
  • Sevillya G; Biomedical Core Facility, Russell Berrie Nanotechnology Institute, Technion-Israel Institute of Technology, Haifa, Israel.
  • Anoze A; The Oncology Institute, Helmsley Cancer Center, Precision Oncology and Innovation, Shaare Zedek Medical Center, 12, Shmuel Beit St, 9103102, Jerusalem, Israel.
  • Refaely Y; Department of Cardiothoracic Surgery, Soroka University Medical Center, Beer-Sheva, Israel.
  • Cohen AY; The Oncology Institute, Soroka University Medical Center, Beer-Sheva, Israel.
  • Melamed I; Department of Neurosurgery, Soroka University Medical Center, Beer Sheva, Israel.
  • Azriel A; Department of Neurosurgery, Soroka University Medical Center, Beer Sheva, Israel.
  • Shoukrun R; Department of Ears, Nose & Throat, Head & Neck Surgery, Soroka University Medical Center, Beer Sheva, Israel.
  • Raviv Y; Pulmonary Institute, Soroka University Medical Center, Beer-Sheva, Israel.
  • Porgador A; The Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.
  • Peled N; The Oncology Institute, Helmsley Cancer Center, Precision Oncology and Innovation, Shaare Zedek Medical Center, 12, Shmuel Beit St, 9103102, Jerusalem, Israel. nirp@szmc.org.il.
  • Roisman LC; The Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel. dr.roisman@gmail.com.
Clin Transl Oncol ; 26(9): 2227-2239, 2024 Sep.
Article en En | MEDLINE | ID: mdl-38553659
ABSTRACT

PURPOSE:

In the pursuit of creating personalized and more effective treatment strategies for lung cancer patients, Patient-Derived Xenografts (PDXs) have been introduced as preclinical platforms that can recapitulate the specific patient's tumor in an in vivo model. We investigated how well PDX models can preserve the tumor's clinical and molecular characteristics across different generations.

METHODS:

A Non-Small Cell Lung Cancer (NSCLC) PDX model was established in NSG-SGM3 mice and clinical and preclinical factors were assessed throughout subsequent passages. Our cohort consisted of 40 NSCLC patients, which were used to create 20 patient-specific PDX models in NSG-SGM3 mice. Histopathological staining and Whole Exome Sequencing (WES) analysis were preformed to understand tumor heterogeneity throughout serial passages.

RESULTS:

The main factors that contributed to the growth of the engrafted PDX in mice were a higher grade or stage of disease, in contrast to the long duration of chemotherapy treatment, which was negatively correlated with PDX propagation. Successful PDX growth was also linked to poorer prognosis and overall survival, while growth pattern variability was affected by the tumor aggressiveness, primarily affecting the first passage. Pathology analysis showed preservation of the histological type and grade; however, WES analysis revealed genomic instability in advanced passages, leading to the inconsistencies in clinically relevant alterations between the PDXs and biopsies.

CONCLUSIONS:

Our study highlights the impact of multiple clinical and preclinical factors on the engraftment success, growth kinetics, and tumor stability of patient-specific NSCLC PDXs, and underscores the importance of considering these factors when guiding and evaluating prolonged personalized treatment studies for NSCLC patients in these models, as well as signaling the imperative for additional investigations to determine the full clinical potential of this technique.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Ensayos Antitumor por Modelo de Xenoinjerto / Medicina de Precisión / Neoplasias Pulmonares Límite: Aged / Animals / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Transl Oncol / Clin. transl. oncol. (Print) / Clinical & translational oncology (Print) Año: 2024 Tipo del documento: Article País de afiliación: Israel Pais de publicación: Italia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Ensayos Antitumor por Modelo de Xenoinjerto / Medicina de Precisión / Neoplasias Pulmonares Límite: Aged / Animals / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Transl Oncol / Clin. transl. oncol. (Print) / Clinical & translational oncology (Print) Año: 2024 Tipo del documento: Article País de afiliación: Israel Pais de publicación: Italia